Navigation Links
FDA Approves New Mechanism of Action Labeling for Ranexa(R)
Date:12/18/2007

PALO ALTO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has approved new language for the product labeling for Ranexa(R) (ranolazine extended-release tablets) which describes the ability of ranolazine to inhibit the late sodium current at therapeutic levels.

Published data on ranolazine's mechanism suggests that during ischemic episodes excess sodium can flow into cardiac cells through sodium channels. This excess sodium can trigger a subsequent overload of calcium that can lead to problems with proper contraction and relaxation of the heart. Late sodium current inhibition has been shown to improve mechanical and electrical dysfunctions of cardiac cells under these circumstances.

"We believe it is important for physicians to have as much information as possible on the mechanism of action for Ranexa and we are very pleased that the FDA has worked with us to add this new language to the approved product labeling," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. Complete product labeling is available at http://www.cvt.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... the transplant recipient,s immune system identifies the transplanted organ ... thought that T cells, the immune cells that mediate ... chemokines in order to migrate to the transplanted organ. ... Investigation , Fadi Lakkis and colleagues at the University ... of T cells is not required for migration. Instead, ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine Group ... 50% enrollment of the total projected enrollment required ... safety and preliminary efficacy of the medical technology ... Knee Osteoarthritis (KOA). To date the trial has ... The Phase I open label clinical research ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... DRRX ) announced today that management is scheduled to present ... -- Needham & Company,s Biotechnology and Medical Technology Conference ... EDT. -- Leerink Swann,s Pain Roundtable Conference, on Monday, June ... Jefferies, 2nd Annual Healthcare Conference on Thursday, June 26th at ...
... June 5 BioTrends Research Group, Inc.,released its ... the management of psoriasis. This report is based ... US Dermatologists in April,2008., According to the ... their use of biologics for the treatment of ...
... BSX ) is scheduled to participate in Goldman ... in Dana Point,CA., Jim Tobin, Boston Scientific Chief ... followed by a 25-minute question and,answer session on Wednesday, ... live webcast of Mr. Tobin,s remarks will be available ...
Cached Biology Technology:Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis 2
(Date:5/16/2013)... A scientist has discovered an ancient extinct creature with ... it in honour of his favourite movie star. ... Kooteninchela deppi (pronounced Koo-ten-ee-che-la depp-eye), which is a ... the actor Johnny Depp for his starring role as ... named Edward, an unfinished creation, who has scissors for ...
(Date:5/16/2013)... outside the bone marrow in the liver, the ... now show that a specific type of immune cell ... Balanced hematopoiesis is essential for the function of the ... in the liver and the spleen. Later the process ... normally serves as the sole source of blood cells ...
(Date:5/16/2013)... the world are meeting next week in Toronto. ... the latest in research findings about the brain, ... the disorders that affect them., "Canada is a ... showcase the best of neuroscience research done here ... of the Canadian Association for Neuroscience. He also ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 2Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... Academy of Sciences will launch the most comprehensive scientific ... terrestrial and marine life forms from the tops of ... They will be joined by colleagues from the University ... National Museum and the Philippines Bureau of Fisheries and ...
... Bethesda, MD FASEB MARC (Minority Access to ... for The Endocrine Society,s 93rd Annual Meeting and Expo ... awards are meant to promote the entry of underrepresented ... the basic science community and to encourage the participation ...
... RUSTON, La. Dr. Yuri Lvov, professor of chemistry ... at Louisiana Tech University, recently led a symposium at ... discussing his application of a more eco-friendly and cost-effective ... properties of plastics, paints and other synthetic composites. ...
Cached Biology News:California Academy of Sciences launches scientific expedition to the Philippines 2California Academy of Sciences launches scientific expedition to the Philippines 3California Academy of Sciences launches scientific expedition to the Philippines 4California Academy of Sciences launches scientific expedition to the Philippines 5Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference 2
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Biology Products: